Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
(WorldNews Japan)

PDF Version Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic women Detailed data from ovulation inhibition study demonstrate 100% ovulation inhibition and 100% return of ovulation upon treatment discontinuation Findings presented during European Society of Human Reproduction and Embryology (ESHRE) virtual 36th Annual Meeting taking place July 5-8, 2020 BASEL, Switzerland, July 06, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the presentation of additional data from clinical studies of its once-daily...